Westren Pharma Atenolol Tablet for Human Medicine

Product Details
Customization: Available
Application: Internal Medicine
Usage Mode: For oral administration
Gold Member Since 2020

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

QA/QC Inspectors
The supplier has 1 QA and QC inspection staff
100% Finished Products Inspection
The supplier inspects 100% of finished products.
Standardized quality control
The supplier has a complete and standardized quality control process, check the Audit Report for more information
R&D Capabilities
The supplier has 1 R&D engineers, you can check the Audit Report for more information
to see all verified strength labels (12)
  • Westren Pharma Atenolol Tablet for Human Medicine
  • Westren Pharma Atenolol Tablet for Human Medicine
Find Similar Products

Basic Info.

Model NO.
tablets
Suitable for
Elderly, Children, Adult
State
Solid
Shape
Tablet
Type
Organic Chemicals
Pharmaceutical Technology
Chemical Synthesis
Dosage
100mg
Use
Oral
Transport Package
Box
Specification
100tablets
Origin
China
Production Capacity
500000box/Month

Product Description

About KEEP OUT OF REACH OF CHILDREN
WE CAN PROVIDE MAKE FORMEULATION (OEM)
 
 
 
Service we can provide:
1. Mixed container, we can mix different items in one container.
2. Quality control, before shipment, free sample for test. After shipment, keep sample for 3 years
3. Prompt shipment with professional documents
4. Packing as your request, with photo before shipment.
 
 
Product Name Atenolol Tablet
Contians Atenolol 100mg
Package 100tablets/box
Store Store at 20° to 25°C (68° to 77°F).
Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.
Application Atenolol (Tenormin) is a beta-blocker that affects the heart and circulation (blood flow through arteries and veins).
Atenolol is used to treat angina (chest pain) and hypertension (high blood pressure).
Atenolol is also used to lower the risk of death after a heart attack.
Hypertension
The initial dose of atenolol is 50 mg given as one tablet a day either alone or added to diuretic therapy. The full effect of this dose will usually be seen within one to two weeks. If an optimal response is not achieved, the dosage should be increased to atenolol 100 mg given as one tablet a day. Increasing the dosage beyond 100 mg a day is unlikely to produce any further benefit.
Atenolol tablets may be used alone or concomitantly with other antihypertensive agents including thiazide-type diuretics, hydralazine, prazosin and alpha-methyldopa.
Angina Pectoris
The initial dose of atenolol is 50 mg given as one tablet a day. If an optimal response is not achieved within one week, the dosage should be increased to atenolol 100 mg given as one tablet a day. Some patients may require a dosage of 200 mg once a day for optimal effect.
Twenty-four hour control with once daily dosing is achieved by giving doses larger than necessary to achieve an immediate maximum effect. The maximum early effect on exercise tolerance occurs with doses of 50 mg to 100 mg, but at these doses the effect at 24 hours is attenuated, averaging about 50% to 75% of that observed with once a day oral doses of 200 mg.

Acute Myocardial Infarction
In patients with definite or suspected acute myocardial infarction, treatment with atenolol I.V. injection should be initiated as soon as possible after the patient's arrival in the hospital and after eligibility is established. Such treatment should be initiated in a coronary care or similar unit immediately after the patient's hemodynamic condition has stabilized. Treatment should begin with the intravenous administration of 5 mg atenolol over 5 minutes followed by another 5 mg intravenous injection 10 minutes later. Atenolol I.V. injection should be administered under carefully controlled conditions including monitoring of blood pressure, heart rate and electrocardiogram. Dilutions of atenolol I.V. injection in Dextrose Injection USP, Sodium Chloride Injection USP, or Sodium Chloride and Dextrose Injection may be used. These admixtures are stable for 48 hours if they are not used immediately.
In patients who tolerate the full intravenous dose (10 mg), atenolol tablets 50 mg should be initiated 10 minutes after the last intravenous dose followed by another 50 mg oral dose 12 hours later. Thereafter, atenolol tablets can be given orally either 100 mg once daily or 50 mg twice a day for a further 6 to 9 days or until discharge from the hospital. If bradycardia or hypotension requiring treatment or any other untoward effects occur, atenolol tablets should be discontinued. (See full prescribing information prior to initiating therapy with atenolol tablets.)
Data from other beta-blocker trials suggest that if there is any question concerning the use of I.V. beta-blocker or clinical estimate that there is a contraindication, the I.V. beta-blocker may be eliminated and patients fulfilling the safety criteria may be given atenolol tablets 50 mg twice daily or 100 mg once a day for at least 7 days (if the I.V. dosing is excluded).
Although the demonstration of efficacy of atenolol is based entirely on data from the first 7 postinfarction days, data from other beta-blocker trials suggest that treatment with beta blockers that are effective in the postinfarction setting may be continued for 1 to 3 years if there are no contraindications.
Atenolol tablets are an additional treatment to standard coronary care unit therapy.

Elderly Patients or Patients with Renal Impairment
Atenolol is excreted by the kidneys; consequently dosage should be adjusted in cases of severe impairment of renal function. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy. Evaluation of patients with hypertension or myocardial infarction should always include assessment of renal function. Atenolol excretion would be expected to decrease with advancing age.
No significant accumulation of atenolol occurs until creatinine clearance falls below 35 mL/min/1.73 m2. Accumulation of atenolol and prolongation of its half-life were studied in subjects with creatinine clearance between 5 and 105 mL/min. Peak plasma levels were significantly increased in subjects with creatinine clearances below 30 mL/min.
The following maximum oral dosages are recommended for elderly, renally-impaired patients and for patients with renal impairment due to other causes:
Creatinine
Clearance
(mL/min/1.73m2)
Atenolol
Elimination
Half-Life
(hrs)
Maximum
Dosage
15 to 35 16 to 27 50 mg daily
< 15 > 27 25 mg daily
Some renally-impaired or elderly patients being treated for hypertension may require a lower starting dose of atenolol: 25 mg given as one tablet a day. If this 25 mg dose is used, assessment of efficacy must be made carefully. This should include measurement of blood pressure just prior to the next dose ("trough" blood pressure) to ensure that the treatment effect is present for a full 24 hours.
Although a similar dosage reduction may be considered for elderly and/or renally-impaired patients being treated for indications other than hypertension, data are not available for these patient populations.
Patients on hemodialysis should be given 25 mg or 50 mg after each dialysis; this should be done under hospital supervision as marked falls in blood pressure can occur.
Cessation of Therapy in Patients with Angina Pectoris
If withdrawal of atenolol tablets therapy is planned, it should be achieved gradually and patients should be carefully observed and advised to limit physical activity to a minimum.
 
   

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier